22.1 Purpose and Scope
- This policy defines requirements for prospective registration, transparent reporting, and public disclosure of clinical trials and other regulated interventional studies across our portfolio. It applies to all human interventional research, regardless of outcome (positive, negative, or null), funding source, or setting.
22.2 What Counts as a “Clinical Trial”
- A clinical trial is any prospective, interventional study in human participants that assigns individuals or clusters to one or more health-related interventions to evaluate effects on health outcomes. This includes drugs, biologics, devices, procedures, behavioral or digital therapeutics, and prevention strategies. Pilot/feasibility trials and cluster trials are in-scope. Observational studies are not trials but may require registry listing when mandated by funders or law.
22.3 Prospective Registration (Mandatory)
- When: Register before enrolling the first participant.
- Where: Use a WHO-recognized public registry (e.g., ClinicalTrials.gov, EU CTR, ISRCTN, ANZCTR, UMIN, CTRI, ChiCTR, PACTR, ReBEC).
- What to include: Unique identifier; brief title; detailed interventions; eligibility; primary/secondary outcomes (with timepoints); sample size; randomization/blinding; sponsor/funder; locations; data-sharing plan (see 22.9).
- Manuscript requirement: Report the registry ID in the abstract or methods and ensure registry and manuscript fields match (title, outcomes, arms).
22.4 Protocols and SPIRIT Compliance
- Provide the full protocol (or an extended methods document) at submission, with version/date.
- Protocols should follow SPIRIT guidance. Any deviations or protocol amendments must be dated and justified in the manuscript and, where possible, updated on the registry.
22.5 Outcome Pre-Specification & Changes
- Primary and secondary outcomes must be pre-specified in the registry and protocol.
- Changes after registration must be time-stamped, reflected on the registry, and explicitly disclosed in the paper with rationale.
- Switching primary outcomes post hoc without disclosure is a serious breach and may lead to editorial action.
22.6 CONSORT-Aligned Reporting
- Trials must follow CONSORT (and relevant extensions: cluster, non-inferiority, pragmatic, pilot/feasibility, harms, CONSORT-AI for AI-enabled interventions). Provide a completed checklist and flow diagram. Report allocation, masking, attrition, analysis sets (e.g., ITT/PP), multiplicity controls, and harms with definitions and ascertainment methods.
22.7 Randomization, Allocation, and Blinding
- Describe sequence generation, allocation concealment, implementation, and any stratification or blocking.
- State who was blinded (participants, caregivers, outcome assessors, analysts) and how blinding integrity was assessed; explain if blinding was not feasible.
22.8 Data Monitoring & Stopping Rules
- Declare whether a Data Safety Monitoring Board (DSMB) was used, its independence, and stopping boundaries.
- Report interim analyses, alpha spending/adjustments, and any early stopping with reasons (efficacy, futility, safety).
22.9 Data Sharing & Access (Trials)
- Include a Data Availability Statement and a Data Sharing Plan consistent with the registry entry: timing (e.g., 6–12 months after publication), scope (de-identified participant data, protocol, SAP), access route (controlled-access repository, DUA terms), and who approves requests.
- Use de-identification standards and controlled-access for sensitive data. Provide metadata and codebooks to enable reuse.
22.10 Results Disclosure Outside the Article
- When required by law or policy, post summary results to the registry within mandated timelines (e.g., 12 months after primary completion, unless an allowed delay applies).
- The manuscript should not be delayed to await registry posting; however, authors must complete required postings as soon as eligible.
22.11 Devices, Diagnostics, and Surgical Trials
- For devices/diagnostics, describe regulatory status (e.g., CE mark, IDE) and the reference standard for diagnostic accuracy.
- For surgical/procedural trials, detail operator expertise, learning curves, standardization, and fidelity monitoring.
22.12 Behavioral and Digital Health Interventions
- Specify the content, intensity, and delivery mode (e.g., app version, algorithm updates), adherence monitoring, and any co-interventions.
- For adaptive/digital trials, document version control, update cadence, and guardrails that prevent silent outcome switching.
22.13 Cluster and Pragmatic Trials
- Define clusters, recruitment windows, and intracluster correlation assumptions used in sample-size and analysis.
- Report CONSORT-Cluster items: cluster creation/allocation, participant identification/consent pathways, and handling of cluster-level covariates.
22.14 Vulnerable Populations & Consent
- For children, cognitively impaired adults, or other vulnerable groups, document assent/guardian consent and additional safeguards.
- If consent was modified (e.g., emergency research with deferred consent), provide the ethics approval and justification.
22.15 Harms, Adverse Events, and Benefit–Risk
- Define adverse events and serious adverse events, collection windows, attribution methods, and grading scales.
- Report all prespecified harms and notable unexpected events, even if none occurred (“no events observed” language must be precise).
22.16 Trial Registration for Non-Drug Interventions
- Registration is required for all interventional human studies, including behavioral, public health, rehabilitation, device, and surgical interventions. Quality-improvement projects that meet trial criteria must register.
22.17 Statistical Analysis and SAP
- Provide or cite a Statistical Analysis Plan (SAP) with version/date.
- Pre-specify primary analysis populations and models, handling of missing data, interim looks, subgroup analyses, and sensitivity checks.
- Report effect sizes with uncertainty (CIs) and exact p-values where appropriate; address multiplicity.
22.18 Trial Registration for Secondary Analyses
- Secondary analyses of a registered trial must clearly link to the parent registration and identify whether analyses were pre-specified or post hoc.
- If new hypotheses/outcomes are introduced, register an ancillary record when feasible and state this in the manuscript.
22.19 Public Health Emergencies & Rapid Evidence
- During emergencies, expedited handling does not waive registration, ethics approvals, or data integrity requirements.
- Preprints and rapid communications must include registry IDs and clear uncertainty language; data sharing should be accelerated within safeguards.
22.20 Transparency, Access to Materials, and Replication
- Provide protocols, SAPs, and key materials (e.g., consent forms, case-report forms) in supplements or repositories when allowed.
- Enable replication by sharing code and de-identified datasets per Section 7; explain justified restrictions and access mechanisms.
22.21 Non-Compliance and Editorial Actions
- At submission: Trials without prospective registration may be rejected or considered only with a prominent Transparency Note explaining the deviation and its impact on bias.
- Post-publication: Failure to disclose registration, undisclosed outcome switching, or non-reporting of primary results may lead to corrections, expressions of concern, or retraction for unreliable reporting.
22.22 Roles, Funding, and Data Access
- State the funder’s role (design, data collection, analysis, interpretation, writing, decision to submit) and who had full data access and verified the data.
- Disclose any contractual limits on publication or data sharing; agreements that allow funder veto or suppression are unacceptable.
22.23 Registration for Expanded Access/Compassionate Use
- Publications arising from expanded-access or compassionate-use programs must not be presented as trials. Clearly label the design, eligibility, monitoring, and limitations.
22.24 Linking and Metadata
- Article metadata include registry identifiers, protocol/SAP DOIs, and funder IDs. Preprints and AAMs should back-link to the same identifiers.
22.25 Continuous Improvement
- We periodically review this policy to align with evolving WHO, ICMJE, and regulatory requirements. Updates are versioned with last-updated dates; journals display any stricter, field-specific rules on their policy pages.